Can Stem Cell-Derived Neurons Treat Parkinson's? Inside the STEM-PD Trial's One-Year Results

In July 2026, researchers from Lund University and the University of Cambridge presented one-year results from STEM-PD, the first European clinical trial to implant pluripotent stem cell-derived dopamine neurons directly into the brains of people with Parkinson's disease. Of eight participants who received the transplant, seven completed one-year follow-up, cells successfully engrafted in all seven, and six were able to reduce their Parkinson's medications while reporting symptom improvement. One participant died of an infection unrelated to the cell product during the trial year. This article walks through what was actually shown, how it compares to other cell-therapy programs in the field, and what still needs to happen before this becomes anything close to an approved treatment.

What STEM-PD Actually Tested

STEM-PD is a Phase I/II, open-label, dose-finding trial — the first pluripotent stem cell therapy trial approved in Sweden and the first cell-replacement therapy trial for Parkinson's disease conducted in Europe, according to the trial's own announcement and Lund University. Eight people with moderately advanced Parkinson's disease, with a median disease duration of roughly 14 years, underwent surgery in 2023–2024 to receive bilateral injections of dopaminergic progenitor cells directly into the putamen, the brain region most depleted of dopamine-producing neurons in Parkinson's. Four participants received a lower cell dose and four received a higher dose. The cells were derived from human embryonic stem cells and manufactured as a cryopreserved, "off-the-shelf" product — meaning they don't require the tissue from multiple aborted fetuses that earlier generations of dopamine cell-replacement research relied on.

Because this is a Phase I/II trial, its primary goal was safety and feasibility, not proof of efficacy. There was no placebo or sham-surgery control group and no blinding — both participants and researchers knew a real transplant had occurred. That matters for how much weight the symptom-improvement findings can bear, a point we return to below.

The One-Year Results, and Why They're Encouraging

The headline finding, presented at the International Society for Stem Cell Research (ISSCR) 2026 annual meeting on July 9, 2026, and reported by Parkinson's UK, the University of Cambridge, and Medical Xpress, is that the transplanted cells engrafted successfully in seven of the eight treated participants. Dopamine PET imaging at six and twelve months showed signal changes in the grafted region consistent with cell survival, and there were no cases of graft-induced dyskinesia (uncontrolled involuntary movements) — a complication that undermined some earlier fetal-tissue transplant trials in the 1990s and 2000s.

Clinically, six of the seven participants who reached one-year follow-up substantially reduced their dopaminergic medication and reported improvement in their symptoms. "The fact that 6 out of 7 trial participants were able to reduce their medication as a result of the treatment is particularly encouraging," said Claire Bale, Associate Director of Research at Parkinson's UK. Malin Parmar, the Lund University neuroscientist who leads STEM-PD, called the data "an important milestone for regenerative medicine approaches in Parkinson's disease," while Cambridge co-investigator Roger Barker described it as "an exciting new departure on repairing the brain." Notably, Parmar also pointed out that independent groups using different dopamine-cell products are reporting comparable safety outcomes — a sign that the broader approach, not just one company's manufacturing process, appears to be reproducible.

Given that Parkinson's currently has no therapy that restores lost neurons — only medications that manage symptoms — evidence that transplanted, lab-grown dopamine neurons can survive, integrate, and coincide with reduced medication need in living human brains is a genuinely significant step, even at this small scale.

The Death That Must Be Disclosed Honestly

One of the eight participants died during the trial year, from a pulmonary infection. Every source we reviewed — Parkinson's UK, Cambridge, RegMedNet, and the STEM-PD trial's own announcement — is consistent that the death was attributed to the infection itself and was not caused by the cell product or the surgical procedure. It occurred during the period when the participant was on immunosuppressive therapy, which is required after this kind of transplant to prevent the immune system from rejecting the grafted cells, and which necessarily raises infection risk. Researchers reported no serious adverse events directly linked to the transplanted cells themselves across the cohort.

This is not a detail to bury. In a trial of only eight people, one death is a substantial event, and it underscores that a full year of immunosuppression is not a trivial cost — it carries real, sometimes serious, risk that has to be weighed against potential benefit.

How This Compares to Other Dopamine Cell-Therapy Programs

STEM-PD is not the only pluripotent stem cell-derived dopamine therapy in clinical testing. BlueRock Therapeutics' bemdaneprocel, also derived from human embryonic stem cells, has reported 36-month data from its own Phase I trial (11 participants across two dose cohorts), showing clinically meaningful reductions in off-state motor scores and increased "good on" time without troublesome dyskinesia, alongside PET evidence that engrafted cells persisted even after immunosuppression was stopped at 12 months. That program has since advanced into exPDite-2, a registrational Phase III trial comparing bemdaneprocel to sham surgery — the kind of controlled, blinded study needed to establish real efficacy. Separately, Japanese researchers led by Jun Takahashi have tested induced pluripotent stem cell (iPSC)-derived dopaminergic cells in a small Kyoto trial. Together, these programs represent a maturing field working from a shared scientific rationale — but each is still years away, at best, from regulatory approval.

Why Standard Treatment Isn't Enough

More than 10 million people worldwide live with Parkinson's disease, according to the Parkinson's Foundation, and current treatment is built around levodopa and other dopamine-replacement medications that ease symptoms but do not slow or reverse the underlying loss of dopamine-producing neurons. Over years of use, many patients develop "on-off" motor fluctuations and dyskinesias as the disease progresses and the brain's capacity to buffer medication swings declines. Advanced delivery systems (infusion pumps, deep brain stimulation) can help manage these fluctuations, but none of the standard options replace the neurons that have been lost. That unmet need is exactly the gap cell-replacement therapies like STEM-PD and bemdaneprocel are trying to address: rather than propping up a failing system with external dopamine, the goal is to rebuild a living source of it inside the brain.

What Still Needs to Happen

STEM-PD's own investigators have been explicit that this is a feasibility milestone, not a demonstration of efficacy. The trial has no control group, so the medication reductions and symptom reports — while encouraging — cannot yet be cleanly separated from placebo effect, natural variation in disease course, or the psychological impact of undergoing major brain surgery. The cohort is tiny: eight people, one of whom died. Long-term durability is unknown; participants are being followed for a planned three years post-transplant to see whether the graft's function holds up or fades. The requirement for a year of immunosuppression is itself a real burden and risk, as this trial's outcome tragically illustrates. Before dopaminergic progenitor cell therapy could become an approved treatment, it will need larger, blinded, sham-controlled Phase III trials of the kind bemdaneprocel has now entered — with pre-specified motor endpoints, standardized "off"-time measurements, and enough patients to detect real treatment effects above the noise of an unblinded, small early-phase study.

Bottom Line

This is real, peer-reviewed evidence that lab-grown dopamine neurons can be safely implanted, survive, and correlate with meaningful symptom improvement in most treated patients — a genuine advance worth taking seriously. It is not an approved therapy, not proven in a controlled trial, and not without real risk, as the one participant death illustrates. If you or someone you care about has Parkinson's and is considering any stem cell-based treatment — whether a legitimate registered trial or a clinic offering unproven "stem cell therapy" — ask specifically: Is this an FDA- or EMA-regulated trial with an IND/CTA and institutional oversight, or an unregulated clinic? What phase is it in, and does it have a control group? What immunosuppression is required, for how long, and what are the infection risks? What happened to prior participants, including any serious adverse events or deaths? And how many years of follow-up data exist so far? Legitimate programs like STEM-PD and bemdaneprocel will have clear, verifiable answers to all of these; clinics selling unproven "stem cell" injections for Parkinson's generally will not.